CivaTech Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CivaTech Oncology sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
CivaTech Oncology: 6 sponsored US clinical trials, 3 recruiting.
CivaTech Oncology sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Squamous Cell Carcinoma of the Skin, with 1 trials.
Upper-quartile sponsor footprint
CivaTech Oncology sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
CivaDerm(TM) Surface Therapy Pilot Study
NCT04480645
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
NCT03290534
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT02843945
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
NCT04033081
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
NCT03109041
Linear Source Registry for Prostate Cancer
NCT02516709
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the CivaTech Oncology pipeline
3 recruiting of 6 indexed (50% open); 2 completed (33%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Squamous Cell Carcinoma of the Skin (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CivaTech Oncology: open-pipeline peers nationwide
Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
CivaTech Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this CivaTech Oncology page
6 registered trials is a research-attention snapshot, not an endorsement of CivaTech Oncology or any single study.
- 3 of CivaTech Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Squamous Cell Carcinoma of the Skin is the condition CivaTech Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Squamous Cell Carcinoma of the Skin trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. CivaTech Oncology pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.